 Wesley Nuffer
Concepts (141)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Students, Pharmacy | 15 | 2023 | 97 | 4.550 |
Why?
| | Community Pharmacy Services | 10 | 2025 | 45 | 4.530 |
Why?
| | Education, Pharmacy | 16 | 2022 | 120 | 4.130 |
Why?
| | Medication Therapy Management | 4 | 2019 | 76 | 2.130 |
Why?
| | Pharmacies | 5 | 2022 | 38 | 1.930 |
Why?
| | Problem-Based Learning | 4 | 2017 | 92 | 1.420 |
Why?
| | Pharmacists | 7 | 2021 | 265 | 1.340 |
Why?
| | Curriculum | 9 | 2023 | 992 | 1.300 |
Why?
| | Pharmacy | 4 | 2023 | 32 | 1.260 |
Why?
| | Diabetes Mellitus | 4 | 2025 | 1040 | 1.230 |
Why?
| | Hypoglycemic Agents | 7 | 2025 | 1291 | 1.110 |
Why?
| | Diabetes Mellitus, Type 2 | 8 | 2025 | 2531 | 1.110 |
Why?
| | Cinnamomum zeylanicum | 2 | 2024 | 2 | 1.080 |
Why?
| | Anti-Obesity Agents | 3 | 2016 | 57 | 1.040 |
Why?
| | Educational Measurement | 5 | 2020 | 289 | 0.930 |
Why?
| | Pharmaceutical Services | 3 | 2023 | 83 | 0.910 |
Why?
| | Receptors, Glucagon | 2 | 2014 | 27 | 0.890 |
Why?
| | Cinnamomum aromaticum | 1 | 2024 | 1 | 0.880 |
Why?
| | Blood Glucose | 3 | 2024 | 2186 | 0.880 |
Why?
| | Plant Preparations | 1 | 2024 | 36 | 0.860 |
Why?
| | Program Development | 4 | 2017 | 364 | 0.770 |
Why?
| | Liraglutide | 3 | 2016 | 30 | 0.720 |
Why?
| | Glucagon-Like Peptide 1 | 3 | 2015 | 135 | 0.610 |
Why?
| | Models, Educational | 1 | 2018 | 93 | 0.560 |
Why?
| | Perception | 2 | 2017 | 359 | 0.530 |
Why?
| | Cardiovascular Diseases | 3 | 2025 | 2111 | 0.510 |
Why?
| | Program Evaluation | 6 | 2020 | 898 | 0.460 |
Why?
| | Drugs, Investigational | 1 | 2014 | 33 | 0.450 |
Why?
| | Rural Health Services | 2 | 2012 | 128 | 0.410 |
Why?
| | Writing | 2 | 2020 | 95 | 0.410 |
Why?
| | Hypoglycemia | 2 | 2014 | 445 | 0.400 |
Why?
| | Public Health | 2 | 2019 | 588 | 0.390 |
Why?
| | Obesity | 2 | 2016 | 2992 | 0.380 |
Why?
| | User-Computer Interface | 1 | 2013 | 159 | 0.370 |
Why?
| | Humans | 35 | 2025 | 137585 | 0.370 |
Why?
| | Clinical Competence | 2 | 2017 | 1118 | 0.360 |
Why?
| | Colorado | 7 | 2020 | 4565 | 0.360 |
Why?
| | Teaching | 1 | 2013 | 224 | 0.350 |
Why?
| | Hyperglycemia | 1 | 2014 | 347 | 0.350 |
Why?
| | Ambulatory Care Facilities | 1 | 2012 | 232 | 0.330 |
Why?
| | Weight Loss | 5 | 2025 | 787 | 0.310 |
Why?
| | Patient-Centered Care | 3 | 2025 | 530 | 0.310 |
Why?
| | Preceptorship | 3 | 2019 | 66 | 0.280 |
Why?
| | Insulin | 2 | 2014 | 2409 | 0.260 |
Why?
| | Patient Care Team | 1 | 2012 | 631 | 0.260 |
Why?
| | Schools, Pharmacy | 2 | 2025 | 47 | 0.260 |
Why?
| | Students | 2 | 2023 | 622 | 0.250 |
Why?
| | Medically Underserved Area | 2 | 2020 | 85 | 0.250 |
Why?
| | Professional-Patient Relations | 2 | 2018 | 145 | 0.220 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 2 | 2014 | 82 | 0.220 |
Why?
| | Quality Improvement | 2 | 2023 | 1178 | 0.210 |
Why?
| | Bias | 1 | 2024 | 218 | 0.200 |
Why?
| | Osteoarthritis | 1 | 2025 | 185 | 0.200 |
Why?
| | Sugars | 1 | 2022 | 41 | 0.190 |
Why?
| | Phytotherapy | 1 | 2022 | 83 | 0.190 |
Why?
| | Clinical Trials, Phase III as Topic | 2 | 2022 | 106 | 0.170 |
Why?
| | Body Weight | 2 | 2015 | 985 | 0.170 |
Why?
| | Trust | 1 | 2021 | 127 | 0.160 |
Why?
| | Dietary Supplements | 1 | 2024 | 561 | 0.160 |
Why?
| | Narration | 1 | 2020 | 58 | 0.160 |
Why?
| | Cost Savings | 1 | 2019 | 84 | 0.150 |
Why?
| | Professional Role | 2 | 2018 | 167 | 0.150 |
Why?
| | Attitude of Health Personnel | 2 | 2020 | 1171 | 0.150 |
Why?
| | Private Practice | 1 | 2018 | 25 | 0.150 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2020 | 1329 | 0.140 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2014 | 3715 | 0.140 |
Why?
| | Canagliflozin | 1 | 2017 | 10 | 0.140 |
Why?
| | Glucosides | 1 | 2017 | 44 | 0.130 |
Why?
| | Benzhydryl Compounds | 1 | 2017 | 73 | 0.130 |
Why?
| | Managed Care Programs | 1 | 2017 | 135 | 0.130 |
Why?
| | Phentermine | 1 | 2016 | 12 | 0.120 |
Why?
| | Patient Care | 1 | 2017 | 111 | 0.120 |
Why?
| | Benzazepines | 1 | 2016 | 39 | 0.120 |
Why?
| | Bupropion | 1 | 2016 | 45 | 0.120 |
Why?
| | Medication Adherence | 1 | 2019 | 467 | 0.120 |
Why?
| | Fructose | 1 | 2016 | 112 | 0.120 |
Why?
| | Health Occupations | 1 | 2015 | 34 | 0.120 |
Why?
| | Rural Population | 1 | 2019 | 563 | 0.120 |
Why?
| | Disease Management | 1 | 2019 | 628 | 0.120 |
Why?
| | Drug Approval | 1 | 2015 | 88 | 0.120 |
Why?
| | Naltrexone | 1 | 2016 | 97 | 0.110 |
Why?
| | Drug Combinations | 1 | 2016 | 343 | 0.110 |
Why?
| | Immunoglobulin Fc Fragments | 1 | 2014 | 41 | 0.110 |
Why?
| | United States Food and Drug Administration | 1 | 2015 | 208 | 0.110 |
Why?
| | Injections, Subcutaneous | 1 | 2014 | 157 | 0.110 |
Why?
| | Medicare | 1 | 2019 | 773 | 0.110 |
Why?
| | Accountable Care Organizations | 1 | 2013 | 10 | 0.110 |
Why?
| | Glucagon-Like Peptides | 1 | 2014 | 58 | 0.100 |
Why?
| | Cough | 1 | 2014 | 122 | 0.100 |
Why?
| | Chronic Disease | 1 | 2019 | 1793 | 0.100 |
Why?
| | Academies and Institutes | 1 | 2013 | 53 | 0.100 |
Why?
| | Forced Expiratory Volume | 1 | 2014 | 531 | 0.100 |
Why?
| | Interprofessional Relations | 1 | 2015 | 283 | 0.100 |
Why?
| | Administration, Inhalation | 1 | 2014 | 688 | 0.100 |
Why?
| | Behavior | 1 | 2013 | 90 | 0.100 |
Why?
| | Drug Administration Schedule | 1 | 2014 | 786 | 0.100 |
Why?
| | Self Report | 1 | 2017 | 827 | 0.100 |
Why?
| | United States | 3 | 2022 | 14841 | 0.100 |
Why?
| | Organizational Objectives | 1 | 2012 | 73 | 0.090 |
Why?
| | Professional Competence | 1 | 2012 | 100 | 0.090 |
Why?
| | Recombinant Fusion Proteins | 1 | 2014 | 665 | 0.090 |
Why?
| | Drug Therapy, Combination | 1 | 2014 | 1066 | 0.090 |
Why?
| | Interdisciplinary Communication | 1 | 2012 | 191 | 0.090 |
Why?
| | Employment | 1 | 2012 | 178 | 0.090 |
Why?
| | Comorbidity | 1 | 2015 | 1622 | 0.080 |
Why?
| | Life Style | 1 | 2013 | 490 | 0.080 |
Why?
| | Retrospective Studies | 2 | 2019 | 15657 | 0.080 |
Why?
| | Clinical Trials as Topic | 1 | 2014 | 1050 | 0.080 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2015 | 1477 | 0.080 |
Why?
| | Health Planning Guidelines | 1 | 2009 | 25 | 0.080 |
Why?
| | Learning | 1 | 2013 | 409 | 0.080 |
Why?
| | Cooperative Behavior | 1 | 2012 | 451 | 0.080 |
Why?
| | Peptides | 1 | 2014 | 985 | 0.070 |
Why?
| | Physician's Role | 1 | 2009 | 211 | 0.070 |
Why?
| | Patient Education as Topic | 1 | 2012 | 766 | 0.070 |
Why?
| | Delivery of Health Care | 1 | 2013 | 951 | 0.060 |
Why?
| | Blood Pressure | 1 | 2012 | 1786 | 0.060 |
Why?
| | Gastric Inhibitory Polypeptide | 1 | 2022 | 14 | 0.050 |
Why?
| | Qualitative Research | 2 | 2020 | 1386 | 0.050 |
Why?
| | Time Factors | 1 | 2013 | 6828 | 0.050 |
Why?
| | Biomarkers | 1 | 2012 | 4149 | 0.040 |
Why?
| | Anecdotes as Topic | 1 | 2020 | 7 | 0.040 |
Why?
| | Competitive Behavior | 1 | 2020 | 43 | 0.040 |
Why?
| | Adult | 1 | 2022 | 37929 | 0.040 |
Why?
| | Benchmarking | 1 | 2019 | 186 | 0.040 |
Why?
| | Self Concept | 1 | 2020 | 253 | 0.040 |
Why?
| | Focus Groups | 1 | 2020 | 522 | 0.030 |
Why?
| | Accreditation | 1 | 2017 | 83 | 0.030 |
Why?
| | Interpersonal Relations | 1 | 2020 | 397 | 0.030 |
Why?
| | Research Report | 1 | 2015 | 83 | 0.030 |
Why?
| | Emotions | 1 | 2020 | 548 | 0.030 |
Why?
| | Faculty | 1 | 2015 | 147 | 0.030 |
Why?
| | Community Networks | 1 | 2013 | 58 | 0.030 |
Why?
| | Pharmacy Service, Hospital | 1 | 2013 | 90 | 0.020 |
Why?
| | Data Collection | 1 | 2012 | 673 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2020 | 5778 | 0.020 |
Why?
| | Internship and Residency | 1 | 2017 | 1147 | 0.020 |
Why?
| | Communication | 1 | 2012 | 879 | 0.020 |
Why?
| | Animals | 1 | 2025 | 36940 | 0.010 |
Why?
| | Male | 1 | 2020 | 67762 | 0.010 |
Why?
| | Female | 1 | 2020 | 73304 | 0.010 |
Why?
|
|
Nuffer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|